The Jerusalem PostPolice transfer Haymanot Kasau case to Lahav 433, protesters mark 1,000 days since her disapperanceInquirerBarbers: VP’s ex-staffers matter may be smokescreen on impeach issueDaily MaverickJUDICIAL TRIBUNAL : Judge Hartle’s defence weighs dismissal bid after witnesses say no racial slur was reportedZDF heuteAktuelle Pressemitteilungen des ZDFسكاي نيوز عربيةإسرائيل.. إصابات إثر دهس استهدف سكانا عربا في كفر قاسمRFI 中文美政府多项签证措施遭联邦法官挡下 国际学生留美及实习限制暂缓InteriaIzrael chce uderzyć ponownie. Netanjahu wywiera presję na TrumpaBillboardBillboard Hot Latin Songs Top 10 Countdown for Nov. 21, 2026 | Billboard LatinDeadlineKathryn Newton, Nina Dobrev, Adam Devine & Scott Eastwood To Star In Rom-Com ‘Sorry About My Friends’ABC NewsWATCH: Animal rescuers describe cat rescue after Brooklyn building collapsePremium TimesConsent, not defence in sex with minors, police warnالشرقالزيدي قرر مواجهتها.. ماذا نعرف عن جماعة "كتائب حزب الله" في العراق؟
The Daily Newsstand · Free, Always
Wednesday, November 18, 2026

Health Canada approves new Eli Lilly GLP-1 pill for weight loss

Translate
Eli Lilly and Company World Headquarters. Lilly makes medicines and pharmaceuticals. Getty Images

Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.

Eli Lilly’s Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.

In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes.

Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP.

Competitor Novo Nordisk manufactures injectables Ozempic and Wegovy, which contain the active ingredient semaglutide. Semaglutide acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada.

Story continues below advertisement

The class of drugs known as GLP-1s have revolutionized weight-loss treatment and experts say some patients may prefer to take a pill rather than an injection.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

There is another GLP-1 pill — Novo Nordisk’s Rybelsus — already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.

The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist.

Because it’s a smaller molecule than peptides semaglutide and tirzepatide, orforglipron can be taken orally and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk.

“It seems to be just as good as if not better” for weight loss as semaglutide and tirzepatide, he said.

The most common side effects of GLP-1 medications — both injectable and oral — include gastrointestinal issues, such as nausea or vomiting.

Ur said whether he would prescribe Foundayo depends on the patient, partly because he is still waiting for clinical trial results on whether or not orforglipron has a cardiovascular benefit like semaglutide and tirzepatide do.

Foundayo received Health Canada authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January.

Story continues below advertisement

There may soon be a second GLP-1 weight-loss pill option in Canada: competitor Novo Nordisk’s Wegovy pill, which is still awaiting Health Canada approval.

Both Foundayo and the Wegovy pill are approved and available in the U.S.

Even though Wegovy is made of the large peptide molecule semaglutide, Novo Nordisk is able to manufacture it in pill form by adding an ingredient called salcaprozate sodium to protect it from being broken down by digestive enzymes.

Once the pill is swallowed, salcaprozate sodium, or SNAC, temporarily makes the area around it less acidic and helps it pass through the stomach lining into the bloodstream, Novo Nordisk spokesperson Kate Hanna said in an email on Wednesday.

View the original on Global News →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.